June S. Almenoff, MD, PhD, FACP



  • Drug Development consultant: 20+ years as successful C-level biopharma executive, including Chief Medical
    Officer and board member, specializing in drug development (Phases 1-4), translational medicine, and commercial strategy. Strong track record in clinical trials, regulatory strategy, medical governance, and risk management. Proven expertise in FDA strategy/meetings submission, entrepreneurship, business development/venture capital, and strategic partnerships.
  • President, CMO, and Board Member of Furiex Pharmaceuticals (acquired by Actavis/Allergan).
  • Chief Operating Officer, CMO, and Strategic Advisor of Innovate BioPharmaceuticals.
  • Public, private biotech and venture philanthropy board experience (see below).
  • Vice President, Clinical Safety/Risk Management at GSK. Member: senior medical governance and labeling boards.
  • GSK-led development of pioneering systems to minimize drug development risk, now industry/regulator standards.
  • Value creation for small companies: integrating clinical development, science, commercial, and regulatory expertise.
  • MD, PhD. Icahn (Mt. Sinai) School of Medicine; Residency/Fellowship, Stanford University; Board-certified, Fellow of the American College of Physicians; more than 50 publications and 20+ invited presentations; 15 years of academic medical and research experience in internal medicine, infectious diseases, molecular biology, and pharmacology, and 10 years of clinical practice.

Preclinical/Clinical Development and Translational Medicine, Clinical Trials (Phases 1-4), Medical Governance, Clinical Safety-Risk Management, Regulatory and Commercial Strategy, Submissions, Product Labeling, Data Mining/Signal Detection, FDA Sponsor Meetings and Advisory Committees, KOL Expert Panels, Medical Affairs, Business Development/Investor Outreach, Scientific Licensing, Investment Due Diligence, and Venture Capital.
Therapeutic Areas: Gastroenterology, Infectious Diseases, Microbiome, Immuno-inflammation/Oncology, Rare Diseases, Neuro/CNS, Regenerative Medicine, General Medicine, Metabolic, Respiratory, Ophthalmology, and Dermatology.
Independent Biopharma Consultant, Board Director (2014-current)

  • Chief Operating Officer/CMO of Innovate BioPharma (celiac and GI immune-inflammatory diseases): led Phase 3 strategy, including FDA negotiation, and served as investor/KOL interface (2018)
  • Executive Chair [currently Board member] of RDD Pharma (an Orbimed gastroenterology/neuro company): fundraising, clinical development/regulatory, and corporate strategy (2015-current)
  • Independent Director of TiGenix (regenerative medicine, stem cells, GI/immuno-inflammation): acquired for $630M
  • Independent Director of BrainStorm Cell Therapeutics: neuro/regenerative cell therapies (2017-current)
  • Investment Advisory Board of Harrington Discovery Institute, University Hospitals Health System, OH (2015-current)
  • Member 2019-Drug Safety Research Unit, International Working Group
  • Consultant with Flagship Ventures (Kaleido Biosciences, a microbiome company), RedHill Biopharma (anti-infective, immuno-inflammation, oncology), and Frequency Therapeutics (hearing/neuro-regeneration)
  • Executive-in-Residence of Hatteras Venture Partners (2015)
  • Consulting (Adjunct) Professor of Medicine, Duke University (2012-current)

President, Principal Executive Officer, and Chief Medical Officer, Furiex Pharmaceuticals (2010-2014)
Responsible for strategic, scientific/medical, and financial/fundraising goals of publicly-traded development-stage pharmaceutical company. Company valuation increased tenfold during 4+-year tenure and was acquired by Actavis (now Allergan) for $1.2B. Oversaw Phases 2/3, NDA filing of Viberzi™ (novel molecule for IBS-d that gained US/EU approval), and successful Phase 2 proof-of-concept trials for novel antibiotic awarded FDA fast track. Led commercial financing deal for Prilogy, and raised $60M in debt financing for Phase 3 trials.
Vice President of Clinical Safety, Head of Global Signal Management, GSK (2005-2010)
Provided medical/scientific leadership, management oversight, benefit-risk management, R&D due diligence, and global regulatory submissions (including NDA, sNDA, labeling) for >30 products, as well as clinical trials (Phases 1-4). Secured FDA/EU approvals for several products. As Director/Senior Director, established and led Pharmacovigilance Risk Management Group, chaired a PhRMA-FDA working group, worked in scientific licensing, and managed global clinical safety teams. Served on CIOMS VI committee (international working group on Signal Detection).

Join Today

Curabitur arcu erat, accumsan id imperdiet et, porttitor at sem. Cras ultricies ligula sed dictum porta. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur non nulla sit amet nisl tempus convallis quis ac lectus. Curabitur arcu erat, accumsan id imperdiet et